These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25552658)

  • 1. Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy.
    Giordano C; Mojumdar K; Liang F; Lemaire C; Li T; Richardson J; Divangahi M; Qureshi S; Petrof BJ
    Hum Mol Genet; 2015 Apr; 24(8):2147-62. PubMed ID: 25552658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent impact of Toll-like receptor 2 deficiency on repair mechanisms in healthy muscle versus Duchenne muscular dystrophy.
    Mojumdar K; Giordano C; Lemaire C; Liang F; Divangahi M; Qureshi ST; Petrof BJ
    J Pathol; 2016 May; 239(1):10-22. PubMed ID: 26800321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.
    Villalta SA; Nguyen HX; Deng B; Gotoh T; Tidball JG
    Hum Mol Genet; 2009 Feb; 18(3):482-96. PubMed ID: 18996917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR4 is a regulator of trained immunity in a murine model of Duchenne muscular dystrophy.
    Bhattarai S; Li Q; Ding J; Liang F; Gusev E; Lapohos O; Fonseca GJ; Kaufmann E; Divangahi M; Petrof BJ
    Nat Commun; 2022 Feb; 13(1):879. PubMed ID: 35169163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice.
    Liang F; Giordano C; Shang D; Li Q; Petrof BJ
    PLoS One; 2018; 13(3):e0194421. PubMed ID: 29561896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10.
    Nitahara-Kasahara Y; Hayashita-Kinoh H; Chiyo T; Nishiyama A; Okada H; Takeda S; Okada T
    Hum Mol Genet; 2014 Aug; 23(15):3990-4000. PubMed ID: 24659498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-γ promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation.
    Villalta SA; Deng B; Rinaldi C; Wehling-Henricks M; Tidball JG
    J Immunol; 2011 Nov; 187(10):5419-28. PubMed ID: 22013114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy.
    Wehling-Henricks M; Sokolow S; Lee JJ; Myung KH; Villalta SA; Tidball JG
    Hum Mol Genet; 2008 Aug; 17(15):2280-92. PubMed ID: 18430716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage plasticity in Duchenne muscular dystrophy: a nexus of pathological remodelling with therapeutic implications.
    Petrof BJ
    J Physiol; 2022 Aug; 600(15):3455-3464. PubMed ID: 34904234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and regulation of CC class chemokines in the dystrophic (mdx) diaphragm.
    Demoule A; Divangahi M; Danialou G; Gvozdic D; Larkin G; Bao W; Petrof BJ
    Am J Respir Cell Mol Biol; 2005 Aug; 33(2):178-85. PubMed ID: 15860797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The slow-release adiponectin analog ALY688-SR modifies early-stage disease development in the D2.
    Bellissimo CA; Gandhi S; Castellani LN; Murugathasan M; Delfinis LJ; Thuhan A; Garibotti MC; Seo Y; Rebalka IA; Hsu HH; Sweeney G; Hawke TJ; Abdul-Sater AA; Perry CGR
    Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1011-C1026. PubMed ID: 38145301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.
    Whitehead NP; Kim MJ; Bible KL; Adams ME; Froehner SC
    Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12864-9. PubMed ID: 26417069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
    Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
    J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPA protects against muscle damage in the mdx mouse model of Duchenne muscular dystrophy by promoting a shift from the M1 to M2 macrophage phenotype.
    Carvalho SC; Apolinário LM; Matheus SM; Santo Neto H; Marques MJ
    J Neuroimmunol; 2013 Nov; 264(1-2):41-7. PubMed ID: 24090650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression profiling in exercised mdx suggests a role for extracellular proteins in the dystrophic muscle immune response.
    Coles CA; Gordon L; Hunt LC; Webster T; Piers AT; Kintakas C; Woodman K; Touslon SL; Smythe GM; White JD; Lamandé SR
    Hum Mol Genet; 2020 Feb; 29(3):353-368. PubMed ID: 31696230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of Muscle T Regulatory Cells and Improvement of Muscular Dystrophic Process in mdx Mice by Blockade of Extracellular ATP/P2X Axis.
    Gazzerro E; Baldassari S; Assereto S; Fruscione F; Pistorio A; Panicucci C; Volpi S; Perruzza L; Fiorillo C; Minetti C; Traggiai E; Grassi F; Bruno C
    Am J Pathol; 2015 Dec; 185(12):3349-60. PubMed ID: 26465071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.